Stock markets today ended the day in green. Both, BSE Sensex and NSE Nifty closed up by almost 1.2 per cent from the previous close on Wednesday. While the Sensex ended the day at 35,843.70, up by over 429 points, the broader market Nifty ended the day’s trade at 10,551.70, up by almost 121 points.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Barring 8 stocks in the 30-share BSE Sensex, all were trading in green at the close. The top gainers on Thursday at the time of closing were Mahindra & Mahindra, Titan, Tata Steel, HCL Technology and Infosys while the top losers were Axis Bank, Hindustan Unilever, Kotak Mahindra Bank, ICICI Bank and Bharti Airtel.

Meanwhile, Mahindra & Mahindra, Hero Motocorp, Cipla, Titan and HCL Technologies were the top gainers on Nifty Fifty on Thursday at the close of day’s trade. The top losers were Axis Bank, UPL Vedanta Limited, Hindustan Unilever and Eicher Motors.

Among major indices, Nifty Auto ended at 6,907.10, almost up by over 2.8 per cent. Nifty Bank traded almost flat today ending the day at 21,953.20, up by just over 11 points. Meanwhile, Nifty IT also ended up by over 2.6 per cent at 15,122.55.

On Wednesday, the stock markets ended up by over 1.2 per cent. While the Sensex closed at 35,414.45, the Nifty 50 ended at 10,430.05.

Today, the rupee was trading at 74.9450 against the USD at 4:20 pm.

World stocks rose for a fourth straight day on Thursday as encouraging coronavirus vaccine trials kept investors` spirits up ahead of what was expected to be a record rebound in U.S. jobs figures later. Economists polled by Reuters expect a bumper 3 million U.S. jobs to have been added in June on top of the 2.5 million created in May, and some generally reassuring data from both Asia and Europe this week.

See Zee Business Live TV Streaming Below:

Despite the ongoing rise in global virus cases, Asian equity markets saw their biggest daily rise in over two weeks overnight, aided by news that a vaccine being trialled by Pfizer and Germany`s BioNTech had been well tolerated in early-stage human tests.

Inputs from Reuters